2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
2
Neoplasms
2
Glioblastoma
2
Carcinoma, Hepatocellular
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Stomach Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Penile Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Hepatitis, Chronic
1
Hepatitis C
1
Head and Neck Squamous Cell Cancer
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
BRCA1/2 Mutation
1
Anus Neoplasms
1
Anal Canal Carcinoma
1
Interventions
Cisplatin
258
Radiotherapy
193
Cetuximab
151
pembrolizumab
123
Docetaxel
97
Fluorouracil
92
Carboplatin
80
Paclitaxel
78
Radiotherapy, Intensity-Modulated
72
Surveys and Questionnaires
46
Nivolumab
42
Drug Therapy
34
Radiation
33
Blood Specimen Collection
27
Erlotinib Hydrochloride
26
Gemcitabine
25
Immunohistochemistry
22
Gefitinib
22
Cyclophosphamide
22
Surgical Procedures, Operative
21
Standard of Care
20
durvalumab
19
Pemetrexed
19
Magnetic Resonance Spectroscopy
19
Radiosurgery
17
Capecitabine
17
Chemotherapy, Adjuvant
16
Celecoxib
16
Biopsy
16
atezolizumab
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
rocakinogene sifuplasmid
×
Clear all
NCT02960594
2018-11-19
TRT-001
Inovio Pharmaceuticals
Phase 1
Completed
93 enrolled